Tvardi Therapeutics Inc Stock Price, News & Analysis

Tvardi Therapeutics (NASDAQ: TVRD) reported third quarter 2025 results and a business update highlighting clinical and cash milestones. The company expects topline Phase 2 TTI-101 HCC data in H1 2026 and healthy volunteer results for next-generation TTI-109 in H1 2026 after its IND went into effect. In October, Tvardi reported that the Phase 2 REVERT IPF trial did not meet its goals and is conducting additional analyses. Financially, Q3 R&D was $3.6M versus $4.8M year-ago, G&A rose to $2.3M from $0.9M, net loss was $5.5M, and cash plus short-term investments were $36.5M, with a runway into Q4 2026.

Tvardi Therapeutics (NASDAQ: TVRD) said company management will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 9:30 AM GMT and will hold investor one-on-one meetings during the event. The conference runs November 17–20, 2025 in London, UK. The presentation will be webcast on the Tvardi investor website and a replay will be available for approximately 90 days following the conference.

This is a presentation by a clinical-stage biopharma focused on oral small-molecule STAT3 inhibitors for fibrosis-driven diseases; the company will discuss its near- and longer-term development and investor outreach at the conference.

Tvardi Therapeutics (NASDAQ: TVRD) reported preliminary Phase 2 REVERT results in idiopathic pulmonary fibrosis showing the study did not meet its goals. 88 patients were randomized to TTI-101 400mg (n=30), 800mg (n=29) or placebo (n=29); 58% received concomitant nintedanib.

Baseline percent predicted FVC was lower in placebo (70.1%) versus TTI-101 arms (74.1%, 81.1%). Discontinuation rates were 10.3% placebo vs 56.7% (400mg) and 62.1% (800mg), driven mainly by gastrointestinal adverse events, higher with nintedanib. At 12 weeks mean FVC change (mL) was placebo -22.2 (n=24), 400mg -61.1 (n=8), 800mg -102.8 (n=13).

Company has $41.0M cash, funding operations into Q4 2026, and expects preliminary topline TTI-109 healthy-volunteer data and TTI-101 HCC Phase 2 data in H1 2026.

Tvardi Therapeutics (NASDAQ: TVRD), a clinical-stage biopharmaceutical company developing oral STAT3-targeting therapies for fibrosis-driven diseases, will participate in the Cantor Global Healthcare Conference. The company's management will engage in a fireside chat on September 4, 2025 at 2:10 PM EDT and conduct one-on-one investor meetings.

The fireside chat will be available via webcast on Tvardi's Investors' website, with replay access for approximately 90 days after the conference.

Tvardi Therapeutics (NASDAQ: TVRD), a clinical-stage biopharmaceutical company, reported its Q2 2025 financial results and business updates. The company completed enrollment in its REVERT IPF Phase 2 trial of TTI-101 for idiopathic pulmonary fibrosis, with topline data expected in Q4 2025. Tvardi also submitted an IND for TTI-109 and completed a merger with Cara Therapeutics to become publicly traded.

Financial highlights include $41.0 million in cash and equivalents, a net income of $4.2 million compared to a $7.0 million loss in Q2 2024, primarily due to a $12.8 million remeasurement gain on Convertible Notes. R&D expenses decreased to $5.8 million, while G&A expenses increased to $3.1 million. The company's cash runway is expected to fund operations into Q4 2026.

Tvardi Therapeutics (NASDAQ: TVRD), a clinical-stage biopharmaceutical company developing oral STAT3-targeting therapies for fibrosis-driven diseases, will participate in the BTIG Virtual Biotechnology Conference. The company's management will engage in a fireside chat on July 30, 2025 at 4:40 PM ET and conduct one-on-one investor meetings.

Investors can access the fireside chat webcast through Tvardi's investor website, with the replay available for approximately 60 days after the conference.

Tvardi Therapeutics (NASDAQ: TVRD) has completed enrollment in its Phase 2 clinical trial of TTI-101 for treating idiopathic pulmonary fibrosis (IPF). The REVERT IPF trial is a randomized, double-blind, placebo-controlled study evaluating TTI-101, an oral small molecule STAT3 inhibitor. The trial focuses on safety and lung function (FVC) endpoints, with topline data expected in Q4 2025.

TTI-101's unique dual mechanism of action inhibits STAT3-driven proliferation while activating T-cells, which has shown promise in preclinical studies by reducing lung fibrosis and restoring lung function. IPF is a chronic, progressive lung disease with poor prognosis, where current treatments only slow progression without halting or reversing fibrosis.

Tvardi Therapeutics (NASDAQ: TVRD), a clinical-stage biopharmaceutical company developing oral small molecule therapies targeting STAT3 for fibrosis-driven diseases, has announced its participation in two upcoming investor conferences. The company will join the Piper Sandler 3rd Annual Virtual Lung Symposium on May 27, 2025, at 11:30 AM ET for a fireside chat. Additionally, Tvardi will present at the Jefferies Global Healthcare Conference in New York on June 4, 2025, at 11:40 AM ET, which will include a corporate presentation and investor meetings. The Jefferies presentation will be available via webcast on Tvardi's Investors' website with a 60-day replay period.

Tvardi Therapeutics (NASDAQ: TVRD) reported its Q1 2025 results and business updates. The company recently completed a merger with Cara Therapeutics, receiving $23.8 million in net cash. This, combined with their December 2024 private placement of $28.3 million, strengthens their financial position. The company expects their cash runway to extend into 2H 2026, supporting operations through key milestones. Tvardi's lead program focuses on TTI-101, a STAT3 inhibitor, with Phase 2 data readouts expected in IPF during 2H 2025. Key upcoming milestones include an IND submission for TTI-109 in 1H 2025, IPF trial results in 2H 2025, and preliminary liver cancer trial data in 1H 2026. The company also announced the publication of TTI-101's Phase 1 results in Clinical Cancer Research and an upcoming presentation at the American Thoracic Society 2025 Conference.